🇺🇸 FDA

Company profile · Sponsor

FATE

FATE THERAPEUTICS INC

FATE · NYSE biotech SAN DIEGO, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

FATE (FATE) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker FATE
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001434316

Pipeline (24)

Search pipeline →

  1. FT819

    FATE

    Lupus Nephritis

    phase 2 mab active

    1 trial

  2. MINOCIN 100 mg capsule rigide

    FATE

    Depression

    phase 2 small molecule active

    1 trial

  3. ProHema-CB

    FATE

    Hematologic Malignancies

    phase 2 mab terminated

    1 trial

  4. ProTmune

    FATE

    Hematologic Malignancies

    phase 2 mab completed

    1 trial

  5. Biological: ProHema-CB

    FATE

    Hematologic Malignancies

    phase 1 mab terminated

    1 trial

  6. FATE-NK100

    FATE

    HER2 Positive Gastric Cancer

    phase 1 small molecule completed

    1 trial

  7. FT500

    FATE

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  8. FT516

    FATE

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  9. FT516

    FATE

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  10. FT522

    FATE

    Relapsed/Refractory B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  11. FT536

    FATE

    Astrocytoma

    phase 1 mab active

    1 trial

  12. FT536

    FATE

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  13. FT538

    FATE

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  14. FT538

    FATE

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  15. FT576 (Allogenic CAR NK cells with BCMA expression)

    FATE

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  16. FT596

    FATE

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  17. FT596

    FATE

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  18. FT819

    FATE

    Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

    phase 1 small molecule active

    1 trial

  19. FT819

    FATE

    Lymphoma, B-Cell

    phase 1 small molecule active

    1 trial

  20. FT819 in B-cell Mediated Autoimmune Diseases

    FATE

    B-cell Mediated Autoimmune Diseases

    phase 1 other active

    1 trial

  21. FT825

    FATE

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  22. FT836

    FATE

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  23. Fludarabine

    FATE

    Hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  24. ProHema-CB Transplant

    FATE

    Metabolic Disorders

    phase 1 mab terminated

    1 trial

Patents (8)

Search patents →

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12398373

    Enhanced immune effector cells and use thereof

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is FATE?

FATE (FATE) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does FATE sponsor?

We track 24 ClinicalTrials.gov-linked programs for FATE, including FT819 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does FATE company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.